Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested) | Decision Base | US/EU | 2014
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all…
Non-Small-Cell Lung Cancer (Previously Treated EGFR Wild-Type/Untested) | DecisionBase | US/EU5/Asia Pacific | 2014
Of the Several Exciting Agents in Late-Stage Development, Do Any Have the Potential to Dramatically Improve Survival? Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all…
Hepatitis C Virus (Primary Care Physicians in an Interferon-Free World: How Will the Availability of Safer and More Effective Oral Therapies Impact the Role of PCPs in Treating HCV Patients?) | Physician & Payer Forum | US | 2014
The market opportunity for hepatitis C virus (HCV) is marked by a large prevalent population and high unmet medical need due to the suboptimal tolerability and efficacy of early, interferon-based…
U.S. Prescriber and Payer Receptivity to Emerging Agents for Treatment-Resistant Depression Amid a Crowded and Increasingly Genericized Market | Physician & Payer Forum | US | 2014
Major depressive disorder (MDD) continues to be a highly prevalent psychiatric disorder. Over 5 million drug-treated MDD patients in the United States fail to respond adequately to treatment with…
Renal Anemia in Chronic Kidney Disease Non-Dialysis | Chart Trends | China | 2014
Through an in-depth review of patient charts, details such as product dosing and titration, switching, concomitant medications and a host of laboratory and patient demographic variables help define…
Patient Access to High-Cost Therapies for CML in LATAM: How Do Payers and Physicians Shape This Crowded and Changing Market? | Physician & Payer Forum | Brazil and Mexico | 2014
The treatment armamentarium for chronic myelogenous leukemia (CML) in Brazil and Mexico includes all three currently marketed tyrosine kinase inhibitors (TKIs): Glivec (imatinib,Novartis) for newly…
